Please login to the form below

Not currently logged in
Email:
Password:

J&J expands its TB research programme

Partners with Indian groups CSIR and IMTECH to develop new treatments

J&J

Johnson and Johnson (J&J) has partnered with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to develop new treatments for tuberculosis (TB).

Scientists from J&J’s public health team will work with scientists from the India-based groups on a research and development programmes to explore more effective, safer, all-oral treatment regimens to tackle the bacterial disease, which is spread quickly through inhaling tiny droplets from coughs or sneezes.

Paul Stoffels, chief scientific officer at J&J, said:  “While we have made great advances in recent years with the approval of new TB medicines, much more needs to be done.

“By bringing together some of India’s brightest minds with our scientists, we increase the potential to achieve major research breakthroughs that can lead to innovative new treatments for the millions of people in India and around the world who suffer from TB.”

The therapy area isn’t a new development for J&J, however, as the group has been working on TB research for nearly 20 years, which led to the approval of bedaquiline in the EU and US.

The pharma giant has also been working on a Conditional Access Programme (CAP) since 2016 to provide the drug free of charge across 156 sites in India.

Sanjiv Navangul, managing director at Janssen India, said: “J&J companies have been serving the healthcare needs of India for 70 years now; and this partnership forms an important part of our commitment to the government’s ‘Make in India’ programme, supporting drug development for a disease that affects more than 2.8 million people in India alone.”

Article by
Gemma Jones

31st August 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Shining a light on the true cost of patient care
Sue Thomas and Paul Midgley, of Wilmington Healthcare, explore how the proposed national patient data sharing scheme would change the NHS...
city
The real-world data conundrum
How data is changing the healthcare industries...
Where is health behaviour change heading?
Cures rely on patient adherence to succeed, and health behaviour change in any non-compliant patient is essential, this post explores where health behaviour change is heading....

Infographics